| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
University of Tennessee-Oak Ridge Graduate School of Biomedical Sciences [J. C. F.] and Biology Division, Oak Ridge National Laboratory [J. P. O., A. W. H.], Oak Ridge, Tennessee 37830, and The Institute for Cancer Research, Fox Chase, Philadelphia, Pennsylvania 19111 [R. M. P.]
The mutagenicity and cytotoxicity of 19 ICR compounds, including 6 reported previously, have been determined in the Chinese hamster ovary/hypoxanthine-guanine phosphoribosyltransferase system. As with other physical and chemical agents, ICR 170 and 191 exhibit a phenotypic expression time of 7 to 9 days, independent of concentrations tested. Thirteen of these compounds are mutagenic. At equimolar concentrations, the compounds with the tertiary amine-type side chain (ICR 217, 340, 355, 368, 170, and 292) are more mutagenic than the compounds with the secondary amine-type side chain (ICR 449, 371, 191, and 372). All secondary amine types show a "plateau" in their concentration-dependent mutagenesis curves at 3 to 4 µM. Shortening of the side chain by one carbon (ICR 171) results in a reduced mutagenicity. Substitution of a sulfur atom for a nitrogen in the side chain (ICR 342) increases both mutagenicity and cytotoxicity. The presence of two 2-chloroethyl groups on the side chain (ICR 220) also results in greatly increased cytotoxicity and mutagenicity. When the 2-chloroethyl group of ICR 340, 372, 292, 191, or 170 is replaced by a 2-hydroxyethyl group (ICR 340-OH, 372-OH, 292-OH, 191-OH, or 170-OH), a mutagenically inactive compound results which remains toxic. Replacement of the amine linkage with an ether linkage (ICR 283) also yields a mutagenically inactive compound.
1 Research supported jointly by the Environmental Protection Agency; the National Center for Toxicological Research; and the Office of Health and Environmental Research, United States Department of Energy, under Contract W-7405-eng-26 with the Union Carbide Corporation.
2 Predoctoral Fellow supported by Grant CA 09104 from the National Cancer Institute. To whom reprint requests should be addressed.
Received 4/30/79. Accepted 9/10/79.
This article has been cited by other articles:
![]() |
A. Olry, P. Chastagner, A. Israel, and C. Brou Generation and Characterization of Mutant Cell Lines Defective in {gamma}-Secretase Processing of Notch and Amyloid Precursor Protein J. Biol. Chem., August 5, 2005; 280(31): 28564 - 28571. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.-D. Chen, J. R. Eshleman, M. R. Aminoshariae, A.-H. Ma, N. Veloso, S. D. Markowitz, W. D. Sedwick, and M. L. Veigl Cytotoxicity and Mutagenicity of Frameshift-Inducing Agent ICR191 in Mismatch Repair-Deficient Colon Cancer Cells J Natl Cancer Inst, March 15, 2000; 92(6): 480 - 485. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Wood, M. S. Wiesener, K. M. Yeates, N. Okada, C. W. Pugh, P. H. Maxwell, and P. J. Ratcliffe Selection and Analysis of a Mutant Cell Line Defective in the Hypoxia-inducible Factor-1 alpha -Subunit (HIF-1alpha ). CHARACTERIZATION OF HIF-1alpha -DEPENDENT AND -INDEPENDENT HYPOXIA-INDUCIBLE GENE EXPRESSION J. Biol. Chem., April 3, 1998; 273(14): 8360 - 8368. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |